ABIVAX (EPA:ABVX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ABIVAX

BRIEF

published on 09/08/2025 at 22:05, 2 months 26 days ago

Abivax Reports First Half 2025 Financial Performance

Financial Results Research And Development Convertible Notes Public Offering Cash Reserves
PRESS RELEASE

published on 09/08/2025 at 22:00, 2 months 26 days ago

Abivax Presents First Half 2025 Financial Results
Abivax presents first half 2025 financial results, revealing operating loss increase and net loss for the period, also updates on clinical programs and public offering

Financial Results Abivax Public Offering Clinical Programs Operating Loss
BRIEF

published on 09/02/2025 at 11:00, 3 months 2 days ago

JP Morgan Chase & Co. Crosses Threshold at ABIVAX

Voting Rights Capital Abivax Threshold Crossing JP Morgan
BRIEF

published on 08/13/2025 at 18:05, 3 months 22 days ago

ABIVAX: Update on capital and voting rights

Euronext Paris Share Capital Voting Rights AMF Abivax
BRIEF

published on 08/13/2025 at 18:05, 3 months 22 days ago

ABIVAX: Share and voting rights data as of July 31, 2025

Euronext Paris Voting Rights Biotechnology Actions AMF Regulations
BRIEF

published on 07/28/2025 at 22:20, 4 months 7 days ago

Abivax Completes $747.5 Million Public Offering

Biotechnology Abivax Ulcerative Colitis Nasdaq Public Offer
PRESS RELEASE

published on 07/28/2025 at 22:15, 4 months 7 days ago

Abivax Announces Closing of $747.5 Million Public Offering
Abivax announces closing of $747.5 million public offering, enabling financing into Q4 2027 and reaching planned milestones for Ulcerative Colitis. ADSs listed on Euronext Paris and Nasdaq Global Market

Abivax Ulcerative Colitis Nasdaq Finance Public Offering
BRIEF

published on 07/25/2025 at 08:05, 4 months 10 days ago

Abivax Raises $747.5M Through ADS Offering

Biotechnology Abivax Nasdaq Capital Increase ADS Offering
PRESS RELEASE

published on 07/25/2025 at 08:00, 4 months 10 days ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 4 months 11 days ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 54 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 34 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 59 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 10 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 14 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 25 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 40 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 41 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 24 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE